|
Aptilon Corporation Revenue Increases 135% for the Three-Month Period Ended March 31, 2007
- January 1 to March 31, 2007 revenues were $2,245,425 an increase of 135% compared to $960,122 for the same period in 2006.
- Net loss amounted to $845,800 for the three months ended March 31, 2007, an increase of 45% from the $582,018 loss during the same period in 2006.
- Started programs for three new pharmaceutical brands with three different clients.
- ? Working capital stood at $5.78 million at March 31, 2007.
Montreal, Quebec, May 30, 2007 - Aptilon Corporation (TSX-V: APZ) announced today results for the three-month period ended March 31, 2007. Complete financial statements and MD&A are available on SEDAR at sedar.com. Revenues for the period were $2,245,425. Revenues increased 135% versus total revenue of $960,122 recognized in the period ended March 31, 2006. Revenues for the current period increased when compared to $1,523,197 revenue recognized in the four-month period ended December 31, 2006, or $1,140,147 in the quarter ended December 31, 2006, calculated on an annualized basis.
The net loss for the three-month period ended March 31, 2007 was $845,800 which represents a basic loss per share of $0.0061 (based on a weighted average number of common shares outstanding of 139,293,363 during the period. The current number of outstanding shares is 139,705,210.) The operating loss for the three-month period ended March 31, 2007 is attributed to additional financing for the growth of physician access and the incremental commitment in direct sales and marketing efforts. The net loss decreased from the net loss incurred for the four-month period ended December 31, 2006 of $1,771,134, or $1,328,350 when calculated on an annualized quarterly basis ended December 31, 2006. At March 31, 2007, the company's working capital position was $5,783,848 compared to $6,542,888 in working capital at December 31, 2006.
“Aptilon’s sales and marketing interactions through the ReachNet™ recruiting network with targeted physicians increased substantially during the quarter” said Denis Martineau, President of Aptilon. “With critical access to hundreds of thousands of identified health care professionals we provide an important alternative channel for pharmaceutical marketers.” Martineau added.
“The release of AxcelRx Live 5.0, Aptilon’s next generation bundle of web-based sales and marketing services featuring live sales representative-physician video detail sessions, enables clients to reach more health care professionals more effectively as part of their professional sales and marketing efforts,rdquo;Martineau expanded.
About Aptilon Corporation
Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach and interact with physicians via the Internet through its innovative AxcelRx Live video detailing (with company reps), virtual programs, e-Sampling, peer selling and other sales and marketing programs. Leading health care companies have adopted Aptilon’s “Sales Force of the Future” model, driving tens of thousands of high-quality rep-physician interactions averaging eight to 10 minutes in length. Aptilon provides the infrastructure necessary for sales representatives to build physician awareness, understanding and preference during all stages of a products life cycle, from pre-launch education through end stage support. For more information, visit www.aptilon.com.
Forward-looking Statements
This news release contains forward-looking information. These statements relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management of Aptilon. A number of factors could cause actual events, performance or results to differ materially from the events performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Aptilon does not assume any obligation to update or revise them to reflect new events or circumstances.
###
The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.
|